Related Experiment Video
Updated: Oct 4, 2025
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Type I interferons and SARS-CoV-2: from cells to organisms.
Paul Bastard1, Qian Zhang2, Shen-Ying Zhang2
1Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA; Department of Pediatrics, Necker Hospital for Sick Children, AP-HP, Paris, France.
Type I interferons (IFNs) are crucial for fighting SARS-CoV-2. Boosting these antiviral proteins early can improve outcomes and combat severe COVID-19 pneumonia by enhancing host defense.
Area of Science:
- Immunology
- Virology
- Infectious Diseases
Background:
- Type I interferons (IFNs) are key antiviral proteins.
- SARS-CoV-2 infection can impair the body's natural type I IFN response.
- Understanding this interplay is vital for combating COVID-19.
Purpose of the Study:
- To review the complex relationship between type I IFNs and SARS-CoV-2.
- To highlight the role of type I IFNs in host defense against SARS-CoV-2.
- To discuss therapeutic implications of type I IFNs in COVID-19.
Main Methods:
- Review of existing scientific literature on type I IFNs and SARS-CoV-2.
- Analysis of in vitro and in vivo studies.
- Examination of clinical data on COVID-19 patients with IFN deficiencies or auto-antibodies.
Main Results:
- SARS-CoV-2 infected cells produce insufficient type I IFNs.
- Viral proteins actively suppress type I IFN production and signaling pathways.
- Type I IFN deficiency in animal models correlates with increased viral load and disease severity.
- Early administration of exogenous type I IFNs demonstrates therapeutic benefits.
- Genetic defects or auto-antibodies against type I IFNs are linked to severe COVID-19 pneumonia in humans.
Conclusions:
- Type I IFNs are essential for effective host defense against SARS-CoV-2.
- Impaired type I IFN function significantly contributes to severe COVID-19.
- Exogenous type I IFNs represent a promising therapeutic strategy for SARS-CoV-2 infection.
Related Concept Videos
01:29Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:40Cell-mediated Immune Responses
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:28Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
01:29Viruses with RNA Genomes
01:24T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...